Dr. Yana Najjar, MD
Claim this profileUPMC Hillman Cancer Center
Area of expertise
Melanoma
Yana Najjar, MD has run 7 trials for Melanoma. Some of their research focus areas include:
Solid Tumors
Yana Najjar, MD has run 5 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
UPMC Hillman Cancer Center
University Of Pittsburgh Medical Center
Clinical Trials Yana Najjar, MD is currently running
Pimonidazole
for Melanoma
Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size fits all treatment approach. Treatment of patients with limited regional disease remains challenging. Patients are typically treated with a combination of surgery, regional therapy, systemic therapy. Data on the management of ITMs is limited, even with the availability of immunotherapy (IMT). This study will use the unique etiology of ITMs to facilitate the understanding of how individual lesions metabolically and immunologically evolve as they move away from the primary tumor site. It is hypothesize that as ITMs move away from the primary melanoma site each will harbor progressively hypermetabolic tumor cells and a harsher microenvironment.
Recruiting
1 award
N/A
6 criteria
Nivolumab
for Cancer
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Recruiting
1 award
Phase 1
20 criteria
More about Yana Najjar, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Yana Najjar, MD has experience with
- Nivolumab
- Pembrolizumab
- Axitinib
- Vusolimogene Oderparepvec (RP1)
- Ribociclib
- Trametinib
Breakdown of trials Yana Najjar, MD has run
Melanoma
Solid Tumors
Skin Cancer
Colorectal Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yana Najjar, MD specialize in?
Yana Najjar, MD focuses on Melanoma and Solid Tumors. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Yana Najjar, MD currently recruiting for clinical trials?
Yes, Yana Najjar, MD is currently recruiting for 6 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Yana Najjar, MD has studied deeply?
Yes, Yana Najjar, MD has studied treatments such as Nivolumab, Pembrolizumab, Axitinib.
What is the best way to schedule an appointment with Yana Najjar, MD?
Apply for one of the trials that Yana Najjar, MD is conducting.
What is the office address of Yana Najjar, MD?
The office of Yana Najjar, MD is located at: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15213 United States. This is the address for their practice at the UPMC Hillman Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.